<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="259">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05157776</url>
  </required_header>
  <id_info>
    <org_study_id>SGHDOT 21-10</org_study_id>
    <nct_id>NCT05157776</nct_id>
  </id_info>
  <brief_title>A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations</brief_title>
  <official_title>Neoadjuvant Sintilimab and Platinum-based Chemotherapy for Resectable Locally Advanced NSCLC Harboring no Driver Mutations: A Prospective, Randomized, Multicenter Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tongji University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tongji University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label study designed to evaluate the safety and efficacy of&#xD;
      neoadjuvant PD-1 antibody plus chemotherapy followed by surgery in resectable stage IIIA&#xD;
      non-small cell lung cancer.&#xD;
&#xD;
      The primary endpoint: pCR rate The second endpoint: MPR, DFS, MRD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, multicenter, phase III randomized controlled clinical study.&#xD;
      Stage IIIA NSCLC patients with EGFR mutation negative and ALK rearrangement negative were&#xD;
      enrolled, and after 2 courses of treatment with Sintilimab combined with Platinum-based&#xD;
      Chemotherapy, they were randomly assigned 1:1 to the control group (surgical resection and&#xD;
      postoperative treatment for 2 courses are recommended) or the experimental group (surgery&#xD;
      after 2 courses of treatment).&#xD;
&#xD;
      The primary endpoint is pCR rate. The second endpoints are MPR, DFS, and MRD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologically complete response (pCR) rate</measure>
    <time_frame>in three weeks after the surgical resection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major pathological response (MPR) rate</measure>
    <time_frame>in three weeks after the surgical resection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>one, two, three and five years since the initial treatment (each treatment is 2 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal residual disease(MRD)</measure>
    <time_frame>in one week before each cycle and in the forth week after the surgical resection (each cycle is 21 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>NSCLC, Stage IIIA</condition>
  <condition>EGF-R Negative Non-Small Cell Lung Cancer</condition>
  <condition>ALK Negative NSCLC</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant therapy of Sintilimab and chemotherapy in 2 cycles before surgery and optional adjuvant therapy of Sintilimab and chemotherapy in 2 cycles after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant therapy of Sintilimab and chemotherapy in 4 cycles before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 and chemotherapy</intervention_name>
    <description>Sintilimab+(Squamous)ABX+DDP/CBP, or (non-Squamous)PEM+DDP/CBP</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Resectable stage IIIA NSCLC, EGFR mutation-negative and ALK rearrangement negative&#xD;
             (8th UICC TNM staging);&#xD;
&#xD;
          2. No prior anti-tumor therapy for NSCLC;&#xD;
&#xD;
          3. Age from 18 to 75 years old;&#xD;
&#xD;
          4. Adequate organ function:&#xD;
&#xD;
             Hemoglobin ≥9.0g/L; White blood cell count 4.0~10×109/L; The absolute value of&#xD;
             neutrophils (ANC) ≥ 1.5×109/L; Platelet count ≥100×109/L; Total bilirubin ≤ 1.5 times&#xD;
             the upper limit of normal; ALT and AST≤2.5 times the upper limit of normal; The&#xD;
             international normalized ratio of prothrombin time is ≤1.5 times the upper limit of&#xD;
             normal value, and the partial thromboplastin time is within the range of normal value;&#xD;
             Creatinine ≤ 1.5 times the upper limit of normal;&#xD;
&#xD;
          5. No chemotherapy, radiotherapy or hormone therapy for malignant tumors, no history of&#xD;
             other malignant tumors, excluding patients who have received hormone therapy for&#xD;
             prostate cancer and have had DFS for more than 5 years;&#xD;
&#xD;
          6. ECOG 0～1;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Double primary or multiple primary NSCLC;&#xD;
&#xD;
          2. EGFR mutation or ALK mutation was positive&#xD;
&#xD;
          3. patients with psychosis;&#xD;
&#xD;
          4. Pre-existing or coexisting bleeding disorders;&#xD;
&#xD;
          5. Other uncontrollable and inoperable patients;&#xD;
&#xD;
          6. Patients whose previous operations have prevented this operation from being performed;&#xD;
&#xD;
          7. Female patients who are pregnant or breastfeeding;&#xD;
&#xD;
          8. For patients who are allergic to the drugs in the program.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiang Fan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai General Hospital; Shanghai Pulmonary Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiang Fan, MD</last_name>
    <phone>15901013210</phone>
    <email>fan_jiang@tongji.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dong Lin, MD</last_name>
    <phone>18121299433</phone>
    <email>dlin2014@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang Fan, MD</last_name>
      <phone>02163240090</phone>
      <email>fan_jiang@tongji.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jiang Fan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 7, 2021</study_first_submitted>
  <study_first_submitted_qc>December 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 14, 2021</last_update_submitted>
  <last_update_submitted_qc>December 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tongji University</investigator_affiliation>
    <investigator_full_name>Jiang Fan</investigator_full_name>
    <investigator_title>Director of Department of Thoracic Surgery</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant</keyword>
  <keyword>PD-1</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Phase III</keyword>
  <keyword>Platinum-based</keyword>
  <keyword>Locally Advanced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

